Seattle Genetics Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) Misses Q2 EPS by 11c, Revenues Beat; Offers FY19 Revenue Guidance
July 16, 2019 4:05 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.49), $0.11 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $28.45 million versus the consensus estimate of $189.81 million.
In the second quarter, we achieved record ADCETRIS net sales in the U.S. and Canada,... More
